Provided by Tiger Trade Technology Pte. Ltd.

ODDITY Tech Ltd.

16.48
+3.4626.53%
Pre-market: 16.490.0125+0.08%05:11 EDT
Volume:11.92M
Turnover:194.91M
Market Cap:760.13M
PE:20.86
High:18.44
Open:17.50
Low:14.57
Close:13.03
52wk High:64.23
52wk Low:9.25
Shares:46.12M
Float Shares:28.59M
Volume Ratio:14.94
T/O Rate:41.69%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.7900
EPS(LYR):1.80
ROE:5.10%
ROA:-0.48%
PB:3.12
PE(LYR):9.16

Loading ...

ODDITY Tech Reports Second Quarter 2026 Results, Expects Sequential Revenue Improvement in the Third Quarter

GlobeNewswire
·
Yesterday

U.S. Earnings Preview: Before Market Open Sept. 9

Dow Jones
·
Yesterday

ODDITY Tech Ltd. Class A (ODD) Receives a Sell from Barclays

TIPRANKS
·
Yesterday

Top News Today/Canada: Carney Vows to Backstop Economy Amid U.S. Trade Row

Dow Jones
·
Yesterday

Oddity Maintained at Hold as Marketing Efficiency Shows Early Improvement but Near-Term Acquisition Headwinds Persist

TIPRANKS
·
Sep 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Sep 08

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Sep 04

Oddity Tech CFO Lindsay Drucker Mann Disposes of USD 128,081.54 in Common Shares

Reuters
·
Sep 04

SL Science Holding Limited Rings Nasdaq Bell, Capping an Active First Quarter as a Publicly Traded Company

GlobeNewswire
·
Sep 03

Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewswire
·
Sep 01

Oddity Tech CFO Lindsay Drucker Mann Disposes of 39,360 Common Shares Worth $587,688.94

Reuters
·
Sep 01

Oddity Tech Files Initial Beneficial Ownership Statement for Director Dave Scott Cohen

Reuters
·
Aug 29

Oddity Tech CFO Lindsay Drucker Mann Disposes of 3,493 Shares for $52,423.93

Reuters
·
Aug 28

RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer

GlobeNewswire
·
Aug 25

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Phase II Clinical Study for First-Line Treatment of Esophageal Squamous Cell Carcinoma Advances to Expansion Stage

GlobeNewswire
·
Aug 25

Oddity Tech Names Ex-Morgan Stanley IM Executive David S. Cohen Independent Director, Audit Committee Member

Reuters
·
Aug 21

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Abstract Published by WCLC: Extended Follow‑Up Shows Continued Efficacy Improvement

GlobeNewswire
·
Aug 20

Press Release: Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates

Dow Jones
·
Aug 06

Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals

GlobeNewswire
·
Aug 06

Immix Biopharma to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewswire
·
Aug 04